ANIK
Anika Therapeutics, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
21.79
close · 2026-10-29
value
30
cheaper than peers30
quality
82
stronger fundamentals82
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.12× | 70 |
| price to sales | 2.35× | 58 |
| forward P/E | 22.94× | 14 |
| EV to EBITDA | 92.65× | 9 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 18.4% | 84 |
| revenue growth | 15.6% | 72 |
| operating margin | 11.4% | 61 |
| return on equity | -2.2% | 51 |
4 of 4 measures available
Facts
| market cap | $292M |
| free cash flow | $3.1M |
| employees | 235 |
| first trade | 1993-05-03 |
| next earnings | 2026-11-06 |
| fundamentals updated | 2026-08-13 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.76 | -3.83 | -5.64 | -1.02 | not reported |
| free cash flow | $4.4M | -$2.9M | -$7.2M | -$3.1M | not reported |
| net income | -$10.9M | -$56.4M | -$82.7M | -$14.9M | not reported |
| revenue | $112.8M | $119.9M | $120.8M | $113.8M | not reported |
| unusual items | not reported | not reported | -$62.2M | $0 | $21.1M |